Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DXCM NYSE:HIMS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDXCMDexCom$73.74+1.9%$64.17$54.11▼$89.98$27.91B1.46.97 million shs9.26 million shsHIMSHims & Hers Health$26.12+2.9%$24.08$13.74▼$70.43$6.05B2.4322.14 million shs20.64 million shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDXCMDexCom+1.94%+2.27%+28.11%+0.42%-15.22%HIMSHims & Hers Health+2.83%+10.16%-0.73%+80.08%-51.12%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDXCMDexCom$73.74+1.9%$64.17$54.11▼$89.98$27.91B1.46.97 million shs9.26 million shsHIMSHims & Hers Health$26.12+2.9%$24.08$13.74▼$70.43$6.05B2.4322.14 million shs20.64 million shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDXCMDexCom+1.94%+2.27%+28.11%+0.42%-15.22%HIMSHims & Hers Health+2.83%+10.16%-0.73%+80.08%-51.12%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDXCMDexCom 2.92Moderate Buy$82.4211.77% UpsideHIMSHims & Hers Health 2.12Hold$28.709.88% UpsideCurrent Analyst Ratings BreakdownLatest DXCM and HIMS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2026DXCMDexCom CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$79.00 ➝ $84.005/26/2026HIMSHims & Hers Health Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$28.00 ➝ $25.005/22/2026HIMSHims & Hers Health UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$23.005/22/2026HIMSHims & Hers Health Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$18.00 ➝ $23.005/19/2026HIMSHims & Hers Health Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$30.00 ➝ $28.005/18/2026DXCMDexCom Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$100.00 ➝ $82.005/18/2026DXCMDexCom BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingUnderweight$67.00 ➝ $64.005/18/2026DXCMDexCom Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$100.00 ➝ $80.005/15/2026DXCMDexCom William BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/13/2026HIMSHims & Hers Health Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$32.00 ➝ $30.005/12/2026HIMSHims & Hers Health Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Sell (D)(Data available from 5/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDXCMDexCom$4.66B6.10$2.82 per share26.13$7.66 per share9.63HIMSHims & Hers Health$2.37B2.55$0.86 per share30.33$1.93 per share13.53Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDXCMDexCom$836.30M$2.3431.5124.421.2019.31%33.33%13.19%7/29/2026 (Estimated)HIMSHims & Hers Health$128.37M-$0.09N/A53.3149.25-0.56%6.10%1.52%8/10/2026 (Estimated)Latest DXCM and HIMS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026HIMSHims & Hers Health$0.04-$0.40-$0.44-$0.40$616.84 million$608.10 million4/30/2026Q1 2026DXCMDexCom$0.47$0.56+$0.09$0.51$1.17 billion$1.19 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDXCMDexComN/AN/AN/AN/AN/AHIMSHims & Hers HealthN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDXCMDexCom0.421.951.64HIMSHims & Hers Health2.181.691.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDXCMDexCom97.75%HIMSHims & Hers Health63.52%Insider OwnershipCompanyInsider OwnershipDXCMDexCom0.28%HIMSHims & Hers Health11.76%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDXCMDexCom11,000385.87 million384.79 millionOptionableHIMSHims & Hers Health2,442231.46 million204.24 millionOptionableDXCM and HIMS HeadlinesRecent News About These CompaniesHims & Hers Expands Integrated Health Access via Platform ExpansionMay 29 at 1:16 PM | finance.yahoo.comHims & Hers Expands Integrated Health Access via Platform ExpansionMay 29 at 12:21 PM | zacks.comHims & Hers rises after over $1M insider buyMay 29 at 8:15 AM | seekingalpha.comHims & Hers shares rally on million-dollar insider purchaseMay 29 at 8:15 AM | msn.comHIMS Stock Eyes Breakout Week: Eight New Partners Fuel Push To Build An All-In-One Health PlatformMay 29 at 3:14 AM | stocktwits.comSHims And Hers Canadian GLP 1 Push Tests Broader Wellness Subscription ThesisMay 29 at 3:14 AM | finance.yahoo.comHims & Hers offers generic semaglutide in CanadaMay 28 at 10:02 PM | drugstorenews.comDHims & Hers Expands Benefits for Active Subscribers With Eight New Health and Wellness PartnersMay 28 at 12:00 PM | businesswire.comHims & Hers Eyes Global Growth: Will $1.15B Eucalyptus Deal Fuel Its Recovery or Dilute Shareholders?...May 28 at 9:10 AM | marketbeat.comNorthwestern Mutual Wealth Management Co. Purchases 56,582 Shares of Hims & Hers Health, Inc. $HIMSMay 28 at 4:36 AM | marketbeat.comHIMS vs. TEM: Which AI Healthcare Stock Offers Better Upside Now?May 27 at 3:54 PM | finance.yahoo.comHims & Hers Gains 5% on Insider BuyingMay 27 at 3:54 PM | finance.yahoo.comHims & Hers Stock Spikes -- Insider Sends Strong Signal With $1 Million BuyMay 27 at 3:54 PM | finance.yahoo.comHims & Hers Gains 5% on Insider BuyingMay 27 at 2:01 PM | gurufocus.comHims & Hers Stock Spikes -- Insider Sends Strong Signal With $1 Million BuyMay 27 at 2:01 PM | gurufocus.comHIMS vs. TEM: Which AI Healthcare Stock Offers Better Upside Now?May 27 at 12:36 PM | zacks.comHIMS Stock Heads For Weekly Loss — But Ex-Netflix CFO Is Buying The Dip Despite BofA’s GLP-1 WarningMay 27 at 5:53 AM | stocktwits.comSHims & Hers Health (NYSE:HIMS) Director David Wells Buys 48,400 SharesMay 27 at 4:34 AM | americanbankingnews.comHims & Hers Health (NYSE:HIMS) Director Buys $1,172,732.00 in StockMay 27 at 4:25 AM | insidertrades.comHims & Hers faces steep climb to hit 2026 guidance as Wegovy churn risk looms, says BofAMay 26, 2026 | proactiveinvestors.comHims & Hers faces steep climb to hit 2026 guidance as Wegovy churn risk looms, says BofAMay 26, 2026 | proactiveinvestors.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesHims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in FocusBy Jessica Mitacek | May 8, 2026Hims & Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery?By Jessica Mitacek | May 12, 2026The Silver Lining of Last Week's Hims & Hers Earnings MissBy Jessica Mitacek | May 21, 20263 Reasons Analysts Love DexComBy Nathan Reiff | May 5, 2026Hims & Hers Eyes Global Growth: Will $1.15B Eucalyptus Deal Fuel Its Recovery or Dilute Shareholders?By Jessica Mitacek | May 28, 2026DXCM and HIMS Company DescriptionsDexCom NASDAQ:DXCM$73.74 +1.40 (+1.94%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$73.35 -0.39 (-0.53%) As of 05/29/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.Hims & Hers Health NYSE:HIMS$26.12 +0.74 (+2.92%) Closing price 05/29/2026 03:59 PM EasternExtended Trading$26.08 -0.04 (-0.16%) As of 05/29/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/25 - 05/29 Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17% Costco’s Strong Quarter Still Leaves Investors With a Valuation Problem MongoDB's AI Advantage Is Starting to Show Up in Results Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys Dollar Tree Keeps Winning After Family Dollar Divorce Salesforce Stock Finds Support as AI Momentum Builds These 3 Software Stocks Are Buying Back Shares Hand Over Fist Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
